PKX BIO
LIVE

Serial Number

99328081

Owner

Bexson Biomedical, Inc.

Attorney

Aaron D. Hendelman

Filing Date

Aug 8, 2025

Add to watchlist:

No watchlists yet
View on USPTO

PKX BIO Trademark

Serial Number: 99328081

PKX BIO is a trademark filed by Bexson Biomedical, Inc. on August 8, 2025. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

Bexson Biomedical, Inc. (4 trademarks)

856 Chelham Way
Santa Barbara, CA 93108

Entity Type: 03

Trademark Details

Filing Date

August 8, 2025

Registration Date

Not Registered

Published for Opposition

July 7, 2026

Goods & Services

Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system-related diseases and disorders

Wearable drug delivery devices sold empty, namely, implantable subcutaneous drug delivery pumps for the delivery of medication for viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system-related diseases and disorders

Medical and scientific research in the fields of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; medical and scientific research and development in the field of pharmaceuticals and drug delivery platforms; providing scientific information, scientific research advisory, and scientific research consultancy in the field of pharmaceuticals and drug delivery devices therefor; pharmaceutical research and development; drug discovery services; computational biology research; research and development services in the fields of bioinformatics, genomics, biotechnology, immunology and pharmaceuticals; biomedical research services and biomedical development services being pharmaceutical drug development services; scientific study and research in the fields of medicine, biomedical technology, and genetics; technical consultancy in the field of scientific research relating to biotechnology and product development for others in the field of biotechnology; pharmaceutical drug development services

Providing medical information, advisory, and consultancy services relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals and regarding the use of drug delivery devices therefor

Industrial chemicals, namely, cyclodextrins for industrial purposes; chemical preparations derived from cyclodextrins, namely, chemicals for industrial purposes and active principles in the nature of active chemical ingredients, complexed by cyclodextrins, for use in the manufacture of pharmaceuticals and medicines; chemicals for use in industry, namely, cyclodextrins and cyclodextrin derivatives for use in the chemical, plastics, paper, agricultural, horticultural, insulation, packaging, pharmaceutical, cosmetic, fragrance, textile, leather, healthcare, food and paint industries; active pharmaceutical ingredients, namely, active chemical ingredients in the nature of salts for use in the manufacture of pharmaceuticals and medicines

Filing History

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 1, 2026 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 9, 2026 CNSA
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jun 9, 2026 GNEN
EXAMINER'S AMENDMENT ENTERED
Jun 9, 2026 XAEC
EXAMINERS AMENDMENT E-MAILED
Jun 9, 2026 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jun 9, 2026 CNEA
ASSIGNED TO EXAMINER
May 22, 2026 DOCK
NOTIFICATION OF FINAL REFUSAL EMAILED
Mar 11, 2026 GNFN
FINAL REFUSAL E-MAILED
Mar 11, 2026 GNFR
FINAL REFUSAL WRITTEN
Mar 11, 2026 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 2, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 2, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 2, 2026 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Dec 23, 2025 GNRN
NON-FINAL ACTION E-MAILED
Dec 23, 2025 GNRT
NON-FINAL ACTION WRITTEN
Dec 23, 2025 CNRT
ASSIGNED TO EXAMINER
Dec 22, 2025 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 18, 2025 NWOS
APPLICATION FILING RECEIPT MAILED
Aug 8, 2025 MAFR
NEW APPLICATION ENTERED
Aug 8, 2025 NWAP